Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

BACKGROUND: Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC). Activation of alternative angiogenesis pathways has been implicated in resistance to BEV. This phase II study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Xie, Hao, Lafky, Jacqueline M., Morlan, Bruce W., Stella, Philip J., Dakhil, Shaker R., Gross, Gerald G., Loui, William S., Hubbard, Joleen M., Alberts, Steven R., Grothey, Axel
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066587/
https://ncbi.nlm.nih.gov/pubmed/32201506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920910913
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados